Viyash Scientific Ltd

VIYASH SCIENTIFIC LIMITED

VIYASH SCIENTIFIC LIMITED has informed BSE about the cessation of Vice President, HR & Administration - XBRL.

VIYASH SCIENTIFIC LIMITED

VIYASH SCIENTIFIC LIMITED has informed BSE about the appointment of a Senior Vice President, Human Resources.

Viyash Scientific Ltd

Viyash Scientific Ltd has announced the appointment of Dr. Mallikharjuna Rao Nagineni as Senior Vice President, Human Resources, and the retirement of Mr. Prasad Lad as Vice President - HR & Administration, effective October 20, 2026.

Viyash Scientific Ltd

Viyash Scientific Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from White Oak Capital Management Consultants LLP.

Viyash Scientific Ltd

Viyash Scientific Ltd has informed about the allotment of 1,35,880 equity shares under the Sequent Scientific Limited Employee Stock Option Plan 2020 and Viyash Scientific Limited Employee Stock Option Scheme 2026.

Viyash Scientific Ltd

Viyash Scientific Ltd has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, confirming the details of securities dematerialized/rematerialized during the period.

Viyash Scientific Ltd

Viyash Scientific Ltd has completed the acquisition of BioForLife Italia S.r.l. for EUR 15.0 million, with a deferred consideration of EUR 1.976 million. The transaction has been completed in accordance with the terms of the Sale and Purchase Agreement.

Viyash Scientific Ltd

Viyash Scientific Ltd has announced the closure of its trading window for Q2 FY 2026-27, effective from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ending September 30, 2026.

Viyash Scientific Ltd

Viyash Scientific Ltd has announced the allotment of 6,12,773 equity shares under the Sequent Scientific Limited Employee Stock Option Plan 2020 and Viyash Scientific Limited Employee Stock Option Scheme 2026. The shares were allotted at exercise prices of Rs. 86 and Rs. 101 per equity share respectively. The issued and paid-up equity share capital of the Company has increased from Rs. 87,98,15,176 to Rs. 88,10,40,722.

Viyash Scientific Ltd

Viyash Scientific Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the sale of 2,47,61,691 equity shares and 2,56,04,156 equity shares by CA Harbor Investments and CA Hull Investments respectively.

Viyash Scientific Ltd

Viyash Scientific Ltd announced its Q1 FY 2026-27 earnings, with revenue from operations growing 20% YoY to Rs. 946 crores, EBITDA growing 59% YoY to Rs. 205 crores, and PAT more than doubling to Rs. 79 crores. The company's balance sheet shows improvement, with net debt decreasing to Rs. 86 crores and net debt to EBITDA ratio improving to 0.1x.

Viyash Scientific Ltd

Viyash Scientific Ltd has made available the audio recording of its earnings call for the unaudited financial results (consolidated and standalone) for the quarter ended June 30, 2026, on its website.

Viyash Scientific Ltd

Viyash Scientific Ltd has published the unaudited financial results for the quarter ended June 30, 2026, in The Financial Express and Nava Telangana newspapers, as per Regulation 30 & 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Viyash Scientific Ltd

Viyash Scientific Ltd has announced its Q1 FY 2026-2027 unaudited financial results, showing a 19.5% YoY revenue growth and 21.6% EBITDA margin. The company has also reported a net debt of ₹861 Mn, a decrease of 19.5% from ₹1,661 Mn in Q4 FY26.

Viyash Scientific Ltd

Viyash Scientific Ltd has announced the voting results and scrutinizer report for its 41st Annual General Meeting (AGM). All resolutions were passed with requisite majority by remote e-voting and e-voting at the AGM. The company has also provided the voting results for the adoption of audited financial statements and the re-appointment of a director.

Viyash Scientific Ltd

Viyash Scientific Ltd has announced the voting results and scrutinizer report for its 41st Annual General Meeting. All resolutions were passed with the required majority. The company has also disclosed the voting results for two resolutions, including the adoption of audited financial statements and the re-appointment of a director.

Viyash Scientific Ltd

Viyash Scientific Ltd held its 41st AGM on August 11, 2026, through video conferencing. The meeting was attended by the required quorum, and the proceedings were conducted smoothly. The Company Secretary, Yoshita Vora, welcomed the members and confirmed the availability of statutory registers and documents for electronic inspection. Dr. Kamal Sharma, the Chairman, conducted the further proceedings and addressed the members on the Company's performance for the year. Dr. Haribabu Bodepudi, the Managing Director & Group CEO, provided a detailed performance overview for the year, key developments, and strategic focus.

Viyash Scientific Ltd

Viyash Scientific Ltd announces Q1 FY 2026-27 unaudited standalone and consolidated financial results, with revenues up 19.5%, EBITDA up 59.2%, and PAT up 114.9%. The company will conduct an earnings call on August 12, 2026.

Viyash Scientific Ltd

Viyash Scientific Ltd has announced the allotment of 10,30,775 equity shares under the Viyash Scientific Limited Employee Stock Option Scheme, 2026, at an exercise price of Rs. 101/- per equity share. The company has also approved the incorporation of a wholly owned subsidiary in Vietnam and investment therein, and subscription of equity shares in Alivira Animal Health Limited through a rights issue.

Viyash Scientific Ltd

Viyash Scientific Ltd's board meeting outcome: approved unaudited financial results, employee stock option scheme, incorporation of a wholly-owned subsidiary in Vietnam, and subscription of equity shares in the subsidiary through a rights issue.